Summary
Camba-Pharma has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €137,100 and a net result of €47,651. Equity is growing by about 40% per year across the filed financial years. Its solvency ranks better than 48% of 22,576 sector peers (NACE 47, financial year 2025). The company has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Directors
1 director, last change in 2023
Camille BAETSLÉ
CurrentDirector (not named in the articles) · since 29-12-2023
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ.
See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
3 of this company's 4 Belgian Official Gazette deeds have not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.
Mandate history
1 person since 2023, 1 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| Camille BAETSLÉ |
|
Owners and capital
Owners
No owners or capital events in the accounts and acts we read.